Biosignature of the endometrium in women with endometriosis

子宫内膜异位症女性子宫内膜的生物特征

• 批准号: 7910154
• 负责人: RUO-PAN HUANG
• 金额: $ 10万
• 依托单位: RAYBIOTECH, INC.
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-09-29 至 2012-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7910154
• 关键词: Accounting; Adolescent; Adverse effects; Affect; Age; Agonist; Algorithms; Angiogenic Factor; Antibodies; Applications Grants; Bioinformatics; Biological Assay; Biological Markers; Biometry; Biopsy; Biopsy Specimen; Cell Adhesion Molecules; Cells; Clinic; Clinical; Communities; Complex; Coupled; DNA-Protein Interaction; Danazol; Data; Data Analyses; Development; Diagnosis; Diagnostic; Diagnostic Procedure; Discipline of Nursing; Discipline of obstetrics; Disease; Endometrial; Endometrium; Environment; Estrogens; Future; General Anesthesia; Goals; Growth Factor; Gynecologic; Gynecology; Health Care Costs; Human; Image; Infertility; Inflammation Mediators; Inflammatory; Investigation; Laparoscopy; Lead; Lesion; Medical; Medroxyprogesterone 17-Acetate; Methods; Microarray Analysis; Modification; Molecular; Molecular Profiling; Operative Surgical Procedures; Patient Care; Patients; Pattern; Pelvic Pain; Peptide Hydrolases; Phase; Phosphorylation; Physicians; Post-Translational Protein Processing; Procedures; Progesterone; Protein Array; Protein Microchips; Proteins; Relative (related person); Research; Research Personnel; Risk; Robotics; Role; Sampling; Screening procedure; Signal Transduction; Site; Specimen; Sterility; Syndrome; Technology; Tissues; Training; Tyrosine Phosphorylation; Universities; Uterine cavity; Woman; analytical method; biosignature; chemokine; chronic pelvic pain; clinical Diagnosis; cost; cost effective; cytokine; disease diagnosis; drug development; endometriosis; experience; flexibility; glycosylation; high throughput screening; innovation; medical schools; novel; novel diagnostics; peer; phase 1 study; protein expression; protein function; protein protein interaction; public health relevance; receptor; reproductive; research study; small molecule; stem; technology development; tool

DESCRIPTION (provided by applicant): Protein and antibody arrays have emerged as a technology to study protein expression and protein function in a high throughput manner. RayBiotech, Inc., as a protein array pioneer company, has developed many unique protein and antibody array technologies and products for the research community. These protein and antibody arrays present a new opportunity to profile protein expression levels in endometriosis patients' samples and identify useful biosignatures for diagnosis, drug development, and patient care. We have now developed innovative platforms that we believe can accelerate the accomplishment of these goals. Currently, there is no safe, easy and cost-effective way to diagnose endometriosis. As the operative procedures for diagnoses are not without risks, many clinicians elect to forgo surgical confirmation of endometriosis, particularly in adolescents and young women. Thus, many women are subjected to empiric therapies without a definitive diagnosis. Standard medical endometriosis treatments include medroxyprogesterone acetate (MPA), danazol and GnRH-agonists; therapies that are only partially effective and commonly produce untoward side effects stemming from estrogen deficiency. Hence, a diagnostic alternative to laparoscopy or other surgical procedures is desperately needed. It is our contention that the protein array technology developed by RayBiotech, Inc can fulfill this need of offering a low cost, simplified alternative for the diagnosis of endometriosis as well as provide a guide in clinical patient management. In this grant application, we will profile the protein expression patterns, tyrosine phosphorylation status, and glycosylation patterns of 247 biomarkers in 50 patients' and 50 control biopsy tissues. The data will be collected and analyzed using biostatistical and bioinformatic tools. From the initial screening, we expect to identify a panel of biomarkers which have power to distinguish normal subjects from endometriosis patients. In phase II, we will develop quantitative antibody arrays to simultaneously detect all relevant biomarkers identified in phase I. The quantitative protein arrays will be used to assay 400 samples of endometriosis and 400 control biopsy tissues, analyze the data using biostatistics and bioinformatics, and develop a prediction algorithm for clinical diagnosis of endometriosis. Furthermore, some key factors identified in this study may stimulate questions into their basic roles in the development and progression of endometriosis which could become the subject of future investigations. Our long term goal is to identify biomarkers and biosignatures for diagnosis and personalized treatment of endometriosis. PUBLIC HEALTH RELEVANCE: Identification of biomarkers for endometriosis will significantly increase benefits for the treatment of endometriosis patients. Combining biomarker platforms developed by RayBiotech and high quality specimens from the Department of Gynecology and Obstetrics, Emory University School of Medicine, we hope to identify a biosignature of the endometrium of endometriosis patients that will provide a low cost, simplified surgical alternative for the diagnosis of this disease.

描述（由申请人提供）：蛋白质和抗体阵列已经作为一种以高通量方式研究蛋白质表达和蛋白质功能的技术而出现。 RayBiotech, Inc. 作为蛋白质阵列先驱公司，为研究界开发了许多独特的蛋白质和抗体阵列技术和产品。这些蛋白质和抗体阵列为分析子宫内膜异位症患者样本中的蛋白质表达水平并识别用于诊断、药物开发和患者护理的有用生物特征提供了新的机会。我们现在已经开发了创新平台，我们相信这些平台可以加速实现这些目标。 目前，还没有安全、简单且经济有效的方法来诊断子宫内膜异位症。由于诊断的手术程序并非没有风险，许多临床医生选择放弃子宫内膜异位症的手术确认，特别是对于青少年和年轻女性。因此，许多女性在没有明确诊断的情况下接受经验性治疗。标准医学子宫内膜异位症治疗包括醋酸甲羟孕酮 (MPA)、达那唑和 GnRH 激动剂；这些疗法仅部分有效，并且通常会因雌激素缺乏而产生不良副作用。因此，迫切需要腹腔镜检查或其他外科手术的诊断替代方案。我们认为，RayBiotech, Inc 开发的蛋白质阵列技术可以满足这一需求，为子宫内膜异位症的诊断提供低成本、简化的替代方案，并为临床患者管理提供指导。 在此拨款申请中，我们将分析 50 名患者和 50 份对照活检组织中 247 种生物标志物的蛋白质表达模式、酪氨酸磷酸化状态和糖基化模式。将使用生物统计和生物信息学工具收集和分析数据。从最初的筛选中，我们期望确定一组能够区分正常受试者和子宫内膜异位症患者的生物标志物。在第二阶段，我们将开发定量抗体阵列，以同时检测第一阶段鉴定的所有相关生物标志物。定量蛋白阵列将用于检测400个子宫内膜异位症样本和400个对照活检组织，利用生物统计学和生物信息学分析数据，并开发子宫内膜异位症临床诊断的预测算法。此外，本研究中确定的一些关键因素可能会引发人们对其在子宫内膜异位症发生和进展中的基本作用的疑问，这可能成为未来研究的主题。我们的长期目标是确定用于子宫内膜异位症诊断和个性化治疗的生物标志物和生物特征。 公共健康相关性：子宫内膜异位症生物标志物的鉴定将显着增加子宫内膜异位症患者治疗的益处。结合 RayBiotech 开发的生物标志物平台和埃默里大学医学院妇产科的高质量标本，我们希望识别子宫内膜异位症患者子宫内膜的生物特征，这将为子宫内膜异位症的诊断提供一种低成本、简化的手术替代方案。这种病。